UBS has reiterated a Buy recommendation for Reckitt Benckiser Group (RBGPF), setting an average one-year price target of $80.05, which implies a 42.80% upside from its recent closing price of $56.06. This positive outlook is underpinned by projected annual revenue growth of 16.96% to 16,355MM and an estimated non-GAAP EPS of 3.96. Institutional sentiment also appears strong, with 453 funds increasing their total ownership by 2.33% in the last quarter, reflecting growing investor confidence.
UBS has reiterated a "Buy" recommendation for Reckitt Benckiser Group (RBGPF) as of October 17, 2025, projecting a significant 42.80% upside from its latest closing price of $56.06 to an average one-year target of $80.05. This positive outlook is underpinned by robust financial projections, including an anticipated 16.96% annual revenue increase to $16,355MM and a non-GAAP EPS of $3.96. Institutional investor sentiment appears largely positive, with 453 funds reporting positions, an increase of 1.12% quarter-over-quarter. Total shares owned by institutions rose by 2.33% to 149,536K shares, and the average portfolio weight dedicated to RBGPF increased by 4.58%, signaling growing confidence among a broad base of institutional investors. However, a closer look at individual fund activity reveals nuanced positioning. While funds like VGTSX and DODFX significantly increased both their shareholdings and portfolio allocations in RBGPF, other major holders such as CIVVX and VTMGX decreased their portfolio allocation by 71.51% and 10.00% respectively, despite increasing their share counts. This suggests a relative de-weighting by some large institutional players, warranting further investigation into their strategic rationale.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
